Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX) Short Interest Update

Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX) saw a significant drop in short interest during the month of March. As of March 15th, there was short interest totalling 40,400 shares, a drop of 52.9% from the February 28th total of 85,700 shares. Currently, 2.4% of the company’s shares are short sold. Based on an average trading volume of 2,050,000 shares, the days-to-cover ratio is presently 0.0 days.

Salarius Pharmaceuticals Stock Performance

Shares of NASDAQ:SLRX traded down $0.05 during trading on Friday, reaching $0.87. The stock had a trading volume of 31,696 shares, compared to its average volume of 1,250,994. Salarius Pharmaceuticals has a 52 week low of $0.81 and a 52 week high of $7.20. The firm’s fifty day moving average is $1.56 and its 200 day moving average is $1.59. The stock has a market cap of $1.50 million, a price-to-earnings ratio of -0.11 and a beta of 0.59.

Salarius Pharmaceuticals (NASDAQ:SLRX) last posted its quarterly earnings data on Friday, March 21st. The company reported ($0.66) earnings per share for the quarter, topping the consensus estimate of ($2.31) by $1.65.

Salarius Pharmaceuticals Company Profile

Salarius Pharmaceuticals, Inc, a clinical-stage biotechnology company, focuses on developing treatments for cancers with unmet medical need. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma.